Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Profound Medical Corp.TSX: PRN.TO

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$6.91M, compared with -$10.68M a year earlier. Trailing-twelve-month income before tax was -$38.59M.

Context

  • Income before tax amounted to 262.9% of revenue in FY2025, up 2.4 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$6.91M or moves back toward the trailing-twelve-month quarterly average of -$9.65M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.91M+16.5% QoQ
Last fiscal yearDec 2025
-$43.06M-54.8% YoY
LTMMar 2026
-$38.59M-19.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.3%——
1 year-54.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(43.06M) USD
Year-over-year change
-54.8%

Income Before Tax vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.3% is the 5th highest of 6, against a peer median of +23.0%.
  • Income before tax amounts to 205.7% of revenue for PRN.TO, versus a peer median of 18.8%.
PRN.TO Competitors
Income Before Tax for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DR.TOMedical Facilities CorporationLTM Mar 2026$56.04M USD+10.0%+32.0%18.4%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$32M CAD+134.4%—20.2%
CRRX.TOCareRx CorporationLTM Mar 2026CA$4.86M CAD+230.5%—1.3%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026-$10.7M USD+23.0%—19.2%
PRN.TOProfound Medical Corp.LTM Mar 2026-$38.59M USD-19.3%—205.7%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026-$42.19M USD-41.0%——
Peer median (excluding PRN.TO) —+23.0%+32.0%18.8%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.